The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Enochian Biosciences, Inc. (“Enochian” or “the Company”) (NASDAQ: ENOB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between January 17, 2018 and June 27, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before September 26, 2022.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Enochian co-founder Serhat Gumrukcu was not a licensed physician and did not hold a verifiable college degree of any type. The Company’s science and technology, credited to Gumrukcu, were not likely to be legitimate. The Company overstated the commercial viability of its product pipeline. The Company’s senior executives were aware of Gumrukcu’s history including fraud. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Enochian, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220729005513/en/